Back to News
Market Impact: 0.15
InflaRx Highlights Positive Phase 1 Findings For Oral Drug Candidate Izicopan; Stock Down
Source: Nasdaq
Healthcare & Biotech
InflaRx announced publication of Phase 1 clinical trial results for izicopan, an experimental oral treatment under development for inflammatory and immune-related diseases. The article provides no trial outcomes or numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
IFRX0.35
More News
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Jefferies raises Inovio stock price target on regulatory win
- Truist raises Vericel stock price target on MACI growth momentum
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)